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Context: Empagliflozin was found to decrease mortality in patients with type 2 
diabetes (T2DM) and a prior cardiovascular (CVD) event. 
Objectives: To establish whether these benefits can be replicated in a real-world 
setting, should be expected with the use of dapagliflozin, and apply to T2DM patients 
at low risk of CVD.   
Design: General Practice, population-based, retrospective cohort study (January 
2013-September 2015). 
Setting: The Health Improvement Network Database (THIN). 
Participants: A total of 22,124 patients (4,444 exposed to dapagliflozin, 17,680 
unexposed T2DM patients), matched for age, sex, body mass index, T2DM duration 
and smoking.  
Main outcome measures: The primary outcome was all-cause mortality in the total 
study (high and low risk for CVD) population expressed as the adjusted incidence rate 
ratio (aIRR) with 95% confidence intervals (CI). As a secondary analysis in the low 
risk population, all-cause mortality and incident cardiovascular disease (CVD) were 
considered. 
Results: Patients with T2DM exposed to dapagliflozin were significantly less likely 
to die from any cause (0.50, 95% CI: 0.33-0.75, p-value = 0.001). Similarly, in low-
risk patients, death from any cause was significantly lower in the exposed to 
dapagliflozin cohort (aIRR: 0.44, 95% CI: 0.25-0.78, p-value = 0.002). The difference 
in the risk of incident CVD did not reach statistical significance between groups in 
low-risk patients (aIRR: 0.89, 95% CI: 0.61-1.31, p-value = 0.546). 
Conclusions: Patients with T2DM exposed to dapagliflozin were at a lower risk of 
death from any cause irrespective of baseline CVD status.  
In a population-based, open cohort study, patients with T2DM exposed to dapagliflozin were 
at a lower risk of death from any cause irrespective of their baseline CVD risk. 
Introduction 
Patients with diabetes mellitus type 2 (T2DM) have a two-fold increased risk of all-
cause mortality and a threefold increased risk of cardiovascular mortality (1). Despite 
this, evidence of a significant mortality benefit with intensive glucose-lowering 
treatment remains debatable (2). Additionally, commonly prescribed glucose-
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lowering medications, such as sulphonylureas and dipeptidyl peptidase 4 inhibitors 
(DPP4i) might not be associated with a favorable cardiovascular risk profile (3,4). 
 The findings of the EMPA-REG OUTCOME trial (5), reporting substantial 
CVD and mortality benefits in patients with T2DM receiving empagliflozin, have 
received intense attention and scrutiny (6-11). In this trial, it was reported that high-
CVD risk patients with T2DM had a significant relative risk reduction in the risk of 
cardiovascular mortality (38%), all-cause mortality (32%), and hospital admission for 
heart failure (35%) when sodium-glucose cotransporter 2 inhibitor (SGLT2i) was 
added to their background therapy. Importantly, the magnitude of effect and the rapid 
onset of action (within 3 months) instigated an ongoing discussion about the potential 
underlying cardioprotective mechanism(s). The haemodynamic effect, resulting from 
osmotic diuresis, the subsequent activation of renin–angiotensin–aldosterone system 
(RAAS) pathways, and/or the modification of glucagon concentrations have all been 
proposed as effectors of the additive cardiovascular benefits (6-10). Synergy with 
RAAS blockade medications (10) and a favorable SGLT2i-induced metabolic 
substrate shift  (12) are also interesting theories warranting further investigation. On 
top of this ongoing discussion, a series of additional, clinically relevant questions 
promptly arises and needs to be addressed in a timely fashion.  
 Firstly, it is important to clarify whether the reported CVD benefits are 
intrinsic to empagliflozin or should be anticipated with the use of other approved 
SGLT2i, such as dapagliflozin. Such trials are currently ongoing, but their results are 
not expected soon. Secondly, the relevance of any beneficial CVD effects of SGLT2i 
in low-risk patients with T2DM is still unknown, since only patients with a prior CVD 
event were included in the EMPA-REG OUTCOME trial. Of note, the same partly 
applies for younger patients with a relatively short duration of diabetes, since 
published data refer to predominantly older patients with long-standing diabetes (7). 
Finally, replicating the beneficial CVD results in a pragmatic setting, other than the 
strict RCT setting, would certainly add to both external validity and generalisability of 
any cardioprotective effects.  
To these ends, we conducted a population-based, retrospective open cohort study 
in which patients with T2DM exposed to any dapagliflozin were compared to 
appropriately matched controls with T2DM, unexposed to dapagliflozin, but receiving 
standard, background antidiabetic medication.  
Research Design and Methods 
Study design 
Population-based, retrospective open cohort study in which patients with T2DM 
exposed to SGLT2i were compared to appropriately matched patients with T2DM 
unexposed to SGLT2i. Age, sex, body mass index (BMI), documented duration of 
T2DM and smoking status were used as the matching parameters. Considering that 
the great majority (almost 90%) of the exposed cohort was treated with dapagliflozin, 
analysis and inferences were restricted to those treated with dapagliflozin and their 
respective controls to promote homogeneity and thus, consolidate the findings. 
Source of data 
Data were derived from The Health Improvement Network database (THIN). This is a 
database of anonymised electronic patient records contributed by general practices 
(GP) using the Vision computer system. It includes records from over 640 UK GPs 
(approximately 12 million patients, of which 3.5 million are actively registered with 
their practices). 
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Study cohort 
The study period was set from 1st January 2013 (study start) to 1st September 2015 
(study end, date of the last data collection). All individuals in the study cohort were 
required to be registered at their practice at least a year before entry into the study. 
The decision to use a one year registration period was made to ensure these are new 
(incident prescriptions) rather than a patient being continued on a prescription that 
was initiated in another practice. Their practice was also required to have been using 
their computer system (Vision) for at least a year prior to their index date and have an 
AMR date (an indicator of practice data quality) prior to their index date in order to 
ensure that the practice was making full use of their system and not under-recording 
important outcomes [13]. 
Exposure 
Any subject administered dapagliflozin at any time point during the observation 
period was identified and recorded first. Individuals were included in the exposed 
cohort if they (i) were aged 18+ years at the index date, (ii) had a diagnosis of 
diabetes mellitus any time before the their index date, (iii) had been initiated 
treatment with dapagliflozin, (iv) remained at their practice at least three months after 
treatment initiation. This date (3 months after dapagliflozin prescription) was assigned 
as the index date for each exposed patient. An intention-to-treat approach was 
followed and exposure was assumed to remain unchanged during the observation 
period. A description of the observed treatment patterns is provided in the Appendix.  
Selection of the unexposed cohort (controls) 
After the completion of the exposed cohort, the identification of the unexposed 
patients (controls) and matching procedure were applied and by definition, no 
“control” was exposed to SGLT2i. For each exposed patient up to four unexposed 
controls were selected. Unexposed patients (controls) (i) were individually matched to 
cases on sex, age at index date (to within one year), BMI (to within 2 kg/m2), duration 
of diabetes (to within two years) and smoking status (ii) should have a diagnosis of 
diabetes any time before their index date, (iii) were (by definition) unexposed to 
SGLT2i. No additional matching variables were used to ensure a balanced selection 
of the unexposed group. The diagnosis of diabetes naturally had to be made any time 
before the index date for all study participants. To avoid immortal time bias, the 
unexposed cohort were matched at the index date of their respective exposed patients 
and are assigned the same index as their respective exposed patients.  
Follow-up 
Exposed and unexposed patients with T2DM were followed up (observation period) 
from the index date until the first of the following events (exit date): patient died; 
patient left practice; last data collection from practice; patient diagnosed with any of 
the following cardiovascular outcomes [myocardial infarction or ischaemic heart 
disease, stroke or transient ischaemic attack (TIA), heart failure or left ventricular 
dysfunction). When cardiovascular events were followed by death the observation 
period was calculated according to the outcome under study. 
Outcomes 
The primary outcome was all-cause mortality (death from any cause during the 
observation period). A composite end-point of CVD outcomes (myocardial infarction 
and ischaemic heart disease, stroke or TIA and heart failure or left ventricular 
dysfunction) served as secondary outcomes in an analysis restricted to low-risk 
population. The low-risk population was defined as the absence of all-CVD outcomes 
(myocardial infarction and ischaemic heart disease, stroke and TIA and heart failure) 
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at baseline. CVD end-points were used as an outcome only in the low-risk subset of 
the study population. This decision was made in order to avoid any bias arising from 
miscoding between incident and prevalent CVD outcomes. Medication-specific 
effects were also considered in the analysis. The validity of the definition of the 
primary outcome in THIN database has been previously documented (14).  
Diagnosis of diabetes mellitus, myocardial infarction and ischaemic heart disease, 
stroke and TIA, and heart failure (inclusive of codes suggestive of left ventricular 
dysfunction) was determined by Read codes 
(http://systems.hscic.gov.uk/data/uktc/readcodes).  
Covariates 
Potential confounders were used as model covariates (on top of matching parameters 
age, sex, BMI, smoking status and duration of diabetes) and were selected on the 
basis of biological plausibility. These covariates were glycated haemoglobin, renal 
function (on the basis of estimated glomerular filtration rate), systolic blood pressure, 
insulin use, the use of lipid-lowering medications, diagnosis of hypertension at 
baseline, diagnosis of peripheral vascular disease at baseline and Townsend 
deprivation index. The latter is a measure of socioeconomic and material deprivation 
with five categories starting from the least to the most deprived, and has been 
validated in THIN database (15). When all-cause mortality was the outcome, 
Charlson’s comorbidity index was also used as a model covariate (16). The index 
encompasses 22 medical conditions weighted 1–6 with total scores ranging from 0–
37, shows marked predictive power for mortality (17) and validated for used in 
primary care setting (18). 
Statistical analysis 
The cohort covariates and matching characteristics were summarised for those 
exposed and unexposed to dapagliflozin using appropriate descriptive statistics. 
Differences between exposed and unexposed groups were investigated using chi-
squared tests (for categorical variables) and t-tests or Mann-Whitney U test for 
continuous variables. Missing data (the extent of which was minimal as shown in the 
Appendix) were handled by multiple imputation techniques (chained equations with 
predicted mean matching). Incidence Rate Ratios (IRR) were calculated using Poisson 
regression. Both crude and adjusted estimates were presented. Statistical significance 
level was set at 0.05 (two-sided) and 95% confidence intervals (CI) were presented. 
All analyses were performed in Stata MP 14.0. This study was approved by the 
relevant Scientific Review Committee (SRC Reference Number: 16THIN032A1). 
Sensitivity, subgroup and supplementary analyses 
Although it was reasonable to assume that dapagliflozin were prescribed exclusively 
to patients with T2DM and Read Codes specific for type 1 diabetes mellitus (T1DM) 
were not included, a supplementary effort to avoid any possibility of sample 
“contamination” with T1DM cases was also made. Therefore, we performed a 
sensitivity analysis by excluding those patients who fulfilled eligibility criteria at 
baseline, but subsequently had a Read Code suggestive of T1DM.  
 To detect any source of spurious causal inference, a supplementary analysis 
was undertaken using the  “negative control” methodology as detailed in Lipsitch et al 
(19) and implemented in a similar study design (20). We used dipeptidyl peptidase-4 
inhibitors (DPP4i) as the negative controls, since it has been shown that no significant 
effect on all-cause mortality should be expected (3), at least in the short tem. Finally, 
a subgroup analysis was undertaken to explore the risk of death from any cause in the 
high-risk subset of the population.  
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Results 
Cohort characteristics  
A total of 22,124 patients (4,444 exposed to dapagliflozin and 17,680 unexposed 
patients with T2DM) constituted the final study population. The mean age and BMI 
were 58.4 years and 34.8 kg/m2 respectively, whereas the mean duration of diabetes 
was approximately nine years. Approximately one fifth of the study population 
(n=4,350) have had a previous CVD event (ischaemic heart disease, stroke and/or 
heart failure). The mean HbA1c in the total study population was 7.7% (61.3 
mmol/mol). A table summarizing key study characteristics on the basis of exposure to 
dapagliflozin is presented in Table 1.  
All-cause mortality  
Patients with diabetes who were administered dapagliflozin were significantly less 
likely to die from any cause compared to matched controls with diabetes under 
standard treatment (Crude IRR: 0.49, 95% CI: 0.33-0.72, p-value = 0.0001, Table 2). 
This finding remained robust after adjusting for key covariates (Adjusted IRR: 0.50, 
95% CI: 0.33-0.75, p-value = 0.001, Table 2 and Figure 1).  
All-cause mortality in the low-risk population 
In the low-risk subset of the study population, patients with diabetes who were 
administered dapagliflozin were significantly less likely to die from any cause 
compared to matched controls with diabetes receiving standard treatment (Crude IRR: 
0.43, 95% CI: 0.25-0.74, p-value = 0.002, Table 2). This finding remained unchanged 
after adjusting for key covariates (aIRR: 0.44, 95% CI: 0.25-0.78, p-value = 0.005, 
Table 2).  
Risk of incident cardiovascular event in the low-risk population 
In the low-risk subset of the study population, no difference in the risk of incident 
CVD was detected between patients with diabetes who were administered 
dapagliflozin and matched controls with diabetes receiving standard treatment (Crude 
IRR: 1.00, 95% CI: 0.70-1.42, p-value = 0.981; aIRR: 0.89, 95% CI: 0.61-1.30, p-
value = 0.55, Table 2).  
Sensitivity, subgroup and supplementary analyses 
Both magnitude and direction of effects remain unchanged in sensitivity analyses 
excluding a subset of participants with a Read Code suggestive of T1DM (Appendix). 
Crude and adjusted risk of death from any cause in the high-risk subset of the 
population was similar in effect size with the one observed in the low-risk subset and 
presented in the Appendix. The findings of the “negative control” analysis were 
supportive of the validity of the study design and no evidence of systemic bias was 
detected.  
Discussion  
 In this observational, population-based analysis involving a total of 22,124 
individuals with T2DM and approximately 16,500 person-years of follow-up, our data 
suggest that patients exposed to dapagliflozin were found to be significantly less 
likely to die from any cause compared to appropriately matched controls receiving 
standard, background antidiabetic medication. This data extends the observations 
from the patients included through the narrowly specified inclusion criteria of the 
trials to the general diabetic population, and shows such patients may similarly 
benefit. Similarly, our data support the contention that treatment with dapagliflozin 
was associated with a reduced risk of death from any cause even in the low-risk 
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population. In contrast, although showing a similar trend, the risk of any CVD event 
was not found to be significantly different between the low-risk exposed cohort and 
unexposed cohort.  
The above results can be interpreted as both confirmatory and novel. They are 
confirmatory and reassuring since both the direction and magnitude of effect observed 
in the total study population are similar to the findings reported in the EMPA-REG 
OUTCOME trial (5) and a relevant meta-analysis of RCTs (21). Importantly, they are 
novel since the favourable findings now relate to dapagliflozin, which might be 
equally effective not only in patients at high-risk for CVD, but in the low-risk 
population as well. Both these end-points have significant clinical and research 
ramifications. Furthermore establishing whether reductions in mortality with SGLT2i 
represent a class effect across all SGLT2i could be a relevant end-point. As all 
patients included in the analysis were treated with dapagliflozin we cannot provide 
evidence of a class effect, but do show the observations extend to dapagliflozin. 
 The findings of the present study should be considered in light of its 
limitations. First, this is retrospective evidence and the possibility of bias inherent to 
this study design should be noted.  Furthermore, the actual number of events was low, 
which is reflected in the wide 95% CIs. Therefore, the accuracy of the reported effect 
size may be undermined and the 95% CIs would provide a rather more solid basis for 
interpretation. Furthermore, the observation period (median of almost a year) may be 
short for CVD outcomes to manifest. Collectively, these shortcomings may have 
resulted in an underpowered analysis, especially with respect to the low-risk 
population that showed a lack of significance for all-CVD. However, both number of 
events and total person-years of follow-up in the present study were above relevant 
minimum requirements (22). The possibility that a bias may exist due to preferential 
prescription of SGLT2i to a specific subgroup of patients with diabetes who had a 
survival benefit may be present but negated by appropriate matching and controlling, 
for example controlling for renal function. However, we cannot completely rule out 
prescription by indication bias. Additionally, no information on education and income 
was available at an individual level. Therefore, we used Townsend score, based on 
postcode, as a proxy for measure of deprivation.  Of note, Charlson Comorbidity 
Index does not include all comorbidities such as debilitating neurological conditions 
(multiple sclerosis) and non-malignant hematological diseases (anemia), and 
therefore, it might be an imperfect measure of comorbidity index on mortality.  
Finally, it was not feasible to explore any difference in cardiovascular mortality 
between groups, since it was not possible to adjudicate on the specific cause of death 
in the present study design. The latter might also be a methodological concern in the 
notion that there is no documentation that risk of death was actually comparable 
between groups at baseline. On the other hand, any major, established risk factor for 
CVD and death was taken into account in the matching process (age, sex, BMI, 
disease duration, smoking) and covariate selection (Charlson’s comorbidity index, 
glycaemic control, hypertension, hyperlipidaemia,  renal function, baseline peripheral 
vascular disease, treatment with insulin and socioeconomic status).  
The (clinical and research) implications of the findings are of great interest. Our 
data indicate the benefits from treatment with SGLT2i observed in high-risk diabetic 
patients are not only reproducible in the general diabetic population, but might also be 
extended to the low-risk population when dapagliflozin is concerned. This 
observation should be further pursued in a trial setting. In case an incremental 
mortality benefit is confirmed in subsequent studies, then treatment with dapagliflozin 
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might then be considered a reasonable option to a broad range of patients with type 2 
diabetes.  
In conclusion, our findings suggest that dapagliflozin might be associated with a 
decrease in all-cause mortality irrespective of the baseline CVD status. 
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Figure 1. All-cause mortality in patients with diabetes under treatment with 
dapagliflozin and controls (cumulative hazards estimates). 
Table 1: Baseline characteristics of the study population on the basis of exposure to 
dapagliflozin. 
  Exposed to dapagliflozin Unexposed cohort 
N 4,444  17,680  
Age (years) 58.3 (10.4) 58.5 (10.4) 
Male  2,605 (58.6)  10,364 (58.6) 
Body Mass Index 35.0 (6.9) 34.7 (6.6)* 
Systolic blood pressure (mmHg) 131.6 (12.9)  132.2 (14.1)* 
Smoking  600 (13.5) 2,373 (13.4)* 
Use of lipid-lowering medications 3,931 (88.4) 14,966 (84.7) 
Estimated Glomerular Filtration Rate 91.7 (22.0) 88.6 (24.8)* 
Townsend  * 
1 903 (20.3) 3,134 (17.7) 
2 825 (18.6) 3,214 (18.3) 
3 1,016 (22.9) 3,744 (21.2) 
4 885 (19.9) 3,886 (22.0) 
5 642 (14.5) 2,966 (16.8) 
Not available 173 (3.9) 709 (4.0) 
Follow-up (months) 9.3 (6.5) 8.9 (6.3)*  
Diabetes-specific characteristics   
Duration (years) 9.8 (6.0) 8.5 (5.5)* 
9.1 (3.8)   7.5 (3.8)  Glycated Hemoglobin A1c (% -mmol/mol) 
76.1 (17.7)  60.0 (18.8)* 
Insulin use 1,325 (29.8)           3,647 (20.6)* 
Key co-morbidities at baseline   
Ischaemic Heart Disease  586 (13.2) 2,613 (14.8)* 
Stroke or  transient ischaemic attack  216 (4.9) 1,043 (5.9)* 
Heart Failure or Left Ventricular Dysfunction 95 (2.1) 590 (3.3)* 
Peripheral Vascular Disease  142 (3.2) 626 (3.5) 
Hypertension  2,449 (55.1) 10,315 (58.3)* 
Low risk n (%)* 3,656 (82.3) 14,118 (79.9)* 
Charlson’s Comorbidity Index  * 
1 1,941 (43.7) 7,526 (42.6) 
2 889 (20.0) 3,582 (20.3) 
3 959 (21.6) 3,558 (20.1) 
4 395 (8.9) 1,624 (9.2) 
5 or more 260 (5.9) 1,390 (8.0) 
CVD:  Cardiovascular disease. Low risk for CVD defined as the absence of ischaemic heart disease, 
stroke/transient ischaemic attack and heart failure/left ventricular dysfunction. Continuous data 
presented as mean (standard deviation) unless otherwise specified. Dichotomous and ordinal data 
presented as N (%). Townsend index is a measure of material deprivation (1 denotes the least deprived 
and 5 the most deprived individuals) *Statistically significant at the level of 0.05 
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Table 2:  Risk of death from any cause and incident cardiovascular disease in 
dapagliflozin cohort compared to standard treatment cohort 
 Exposed to 
dapagliflozin 
Unexposed Crude 
IRR 
(95%CI) 
P-
value 
Adjusted IRR* 
(95%CI) 
P-value 
Total population  
Person-years 3,456 13,129     
Death from any cause 29 226     
Incidence rate ( deaths 
per 1000 person-years) 
8.39 17.2 0.49 (0.33-
0.72) 
0.0001 0.50 (0.33-0.75) 0.001 
Low-risk population 
Person-years 2,842 10,514     
Death from any cause 15 128     
Incidence rate (deaths 
per 1000 person-years) 
5.27 12.17 0.43 (0.25-
0.74) 
0.002 0.44 (0.25-0.78) 0.005 
Person-years (CVD) 2,839 10488     
Incident CVD  38 141     
Incidence rate (CVD 
per 1000 person-years) 
13.38     13.43 1.00 (0.70-
1.42) 
0.981 0.89 (0.61-1.30) 0.546 
CI: Confidence Interval, CVD: Cardiovascular Disease, IRR: Incidence Rate Ratio, *Adjusted for age, 
gender,  body mass index, smoking, glycated haemoglobin A1c, duration of diabetes, systolic blood 
pressure, lipid lowering medication, insulin use, estimated glomerular filtration rate, social deprivation 
index, presence of hypertension and Charlson’s comorbidity index  | |  Charlson’s comorbidity index  
was not used as a covariate in incident CVD outcomes | P-values derived from poisson regression | 
Incident CVD was defined as the new diagnosis of either ischaemic heart disease, stroke or transient 
ischaemic attack or heart failure or left ventricular dysfunction in the low risk subset of the population 
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